Health Canada, the federal department responsible for helping Canadians maintain and improve their health, has advised consumers that it has stopped the sale of the anti-inflammatory drug Prexige (lumiracoxib) and will cancel the drug's market authorization due to potential serious liver-related adverse events (hepatitis)...